This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
The Columbia Otolaryngology Department is interested in understanding the intersection of vaping, smell, and taste and their impact on individuals' preferences for certain flavors. Participation will involve answering a series of questionnaires in addition to completing a formal evaluation of your smell and taste with standardized measurements. You can…